Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis
September 27, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 27, 2022 (GLOBE NEWSWIRE) -- BentrioTM nasal spray becomes available again in selected European countries Marketing focus is on protection against airborne allergens...
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19
September 13, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Study has reached extended enrollment target of 160 patients Top-line data read-out expected in Q4-22 Altamira Therapeutics Ltd....
Altamira Therapeutics to Host Investor Call on September 14th
September 08, 2022 08:57 ET
|
Altamira Therapeutics Ltd
HAMILTON, Bermuda, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today...
Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit
September 08, 2022 07:17 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 08, 2022 (GLOBE NEWSWIRE) --Company’s Chief Scientific Officer Samuel Wickline, MD, to present on the Company’s innovative and patented OligoPhoreTM platform for the...
Altamira Therapeutics Provides Business Update
August 30, 2022 09:24 ET
|
Altamira Therapeutics Ltd
Company progressing with plans to focus on its RNA businessAdvancing discussions for divestiture or spin-off of legacy assets, including BentrioTM and AM-125 nasal spraysBentrio revenues were $1.3...
Altamira Therapeutics’ CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic Transformation
August 03, 2022 12:15 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Aug. 03, 2022 (GLOBE NEWSWIRE) -- Altamira’s patented RNA delivery technology platform is addressing strong need for reaching target cells outside the liver and for enhanced...
Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19
August 01, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Enrollment to be continued to 160 subjects, adding 24 to ensure adequate statistical powerTop-line data read-out from trial expected in early...
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal
July 28, 2022 08:47 ET
|
Altamira Therapeutics Ltd
Independent peer-reviewed study confirms high potential for OligoPhore™ delivery platform in RNA-based treatments for osteoarthritisKnock down of JMJD3 gene remarkably mitigated severity of joint...
Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint
July 25, 2022 08:47 ET
|
Altamira Therapeutics Ltd
Company’s novel drug development program AM-411 builds on positive animal dataTreatments for rheumatoid arthritis represent the second largest therapeutic area globally AM-411 to run concurrently...
Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy
July 19, 2022 08:47 ET
|
Altamira Therapeutics Ltd
Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatmentsDemonstrates effective uptake and transfection capacity of Altamira’s proprietary delivery...